Table 1. Updated daratumumab safety profile (from CASTOR) after 48 months of follow-up. The most common (≥20% of patients) and grade 3 and 4 (≥5%) of patients) TEAEs.19 From Weisel et al, 2019.19 Reproduced with permission from Janssen